Staff editor
Theresa Pizarro, (Case Western Reserve University School of Medicine) discussed the roles of epithelial barrier’s cytokines, gut microbiome and Gasdermin in IBD patients.
Sudarshen Paramsothy (University of New South Wales, Australia) discussed the controversials about FMT in IBD patients.
Herbert Tilg (University Innsbruck, Austria) discussed the relationship between Inflammatory Bowel Diseases and gut microbiome.
Niall Hyland (University College Cork) discussed the research on gut brain axis and the potential role of psychobiotics.
Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.
The partnership program aims to develop next-generation probiotics and therapeutics to modulate the gut microbiota to target areas like anxiety, depression and mental well-being.
It's the second agreement between Boehringer Ingelheim and BiomX focused on IBD. The first one in 2020.
Locus is developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases.
New publication reveals how a keystone strain exerts potential to impact a spectrum of health outcomes through immune and metabolic regulation.
A Transdisciplinary Doctoral Programme managed by the University of Naples Federico II through its Task Force on Microbiome Studies.
